Send us a Text Message.In this week’s episode of On The Pen Live, guest Scott Liberto of PlanetScott.com joins to discuss his experience in the Survodutide clinical trial.Survodutide is an investigational dual agonist targeting both the glucagon and GLP-1 receptors, developed by Boehringer Ingelheim in collaboration with Zealand Pharma. This novel drug is designed to treat obesity and metabolic dysfunction-associated steatohepatitis (MASH). Support the Show.MY WORK RELIES ON YOUR GENEROS...